← FDA DRUG APPROVALS

FDA NDA · NDA204063

TECFIDERA

dimethyl fumarate

Sponsor: BIOGEN

APPLICATION
NDA204063
TYPE
NDA
ORIGINAL APPROVAL
2013-03-27
LATEST ACTION
2024-03-12
ROUTE
ORAL
DOSAGE FORM
CAPSULE, DELAYED RELEASE
MARKETING STATUS
Prescription

Products

TECFIDERA · ReferencePrescription
DIMETHYL FUMARATE 120MG · CAPSULE, DELAYED RELEASE · ORAL
TECFIDERA · ReferencePrescription
DIMETHYL FUMARATE 240MG · CAPSULE, DELAYED RELEASE · ORAL

Approval history

2024-03-12Labeling · Supplement 31 · standardLabelAP
2023-12-13Labeling · Supplement 32 · standardLetterAP
2023-02-10Efficacy · Supplement 29 · standardLetterAP
2022-09-29Labeling · Supplement 28 · standardLetterAP
2022-09-29Labeling · Supplement 30 · standardLetterAP
2022-02-10Labeling · Supplement 27 · standardLabelAP
2021-01-29Labeling · Supplement 26 · standardLabelAP
2020-02-05Efficacy · Supplement 23 · standardLetterAP
2019-12-11Labeling · Supplement 25 · standardLetterAP
2019-07-10Labeling · Supplement 24 · standardLetterAP
2017-12-15Labeling · Supplement 20 · standardLetterAP
2017-01-19Labeling · Supplement 17 · standardLabelAP
2016-02-29Labeling · Supplement 14 · standardLabelAP
2015-12-24Manufacturing (CMC) · Supplement 15 · standardAP
2015-10-16Manufacturing (CMC) · Supplement 13 · standardAP
2015-07-14Manufacturing (CMC) · Supplement 12 · standardAP
2015-06-16Manufacturing (CMC) · Supplement 11 · standardAP
2015-03-06Manufacturing (CMC) · Supplement 6 · standardAP
2014-12-03Efficacy · Supplement 3 · standardLabelAP
2014-12-03Labeling · Supplement 10 · standardLabelAP
2014-12-03Labeling · Supplement 8 · standardLabelAP
2014-11-14Labeling · Supplement 9 · standardLetterAP
2014-08-18Manufacturing (CMC) · Supplement 5 · standardAP
2013-08-20Manufacturing (CMC) · Supplement 2 · standardAP
2013-03-27Type 1 - New Molecular Entity · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →